Limits...
IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.

Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J - J Cachexia Sarcopenia Muscle (2011)

Bottom Line: No effect on fat mass was observed.Low-dose IGF-1 significantly reduced mortality (HR = 0.45, 95%CI = 0.21-0.93, p = 0.0315), whilst the high dose did not reach significance (HR = 0.68, 95%CI = 0.26-1.74, p = 0.42).CONCLUSION: Low-dose IGF-1 reduced mortality and attenuated loss of body weight as well as muscle mass in the Yoshida hepatoma rat model.

View Article: PubMed Central - PubMed

ABSTRACT
BACKGROUND: A hallmark symptom of cancer cachexia is the loss of skeletal muscle. This is at least partially due to a deregulation of the growth hormone/IGF-1 axis and a subsequently impaired protein synthesis in skeletal muscle. Here, we investigated the effect of IGF-1 supplementation in a rat model of cancer cachexia. METHODS: Juvenile rats were inoculated with the Yoshida AH-130 hepatoma and treated once daily with 0.3 mg kg(-1) day(-1) (low dose) or 3 mg kg(-1) day(-1) (high dose) IGF-1 or placebo for a period of maximal 16 days. Body weight and body composition (by NMR) were assessed at baseline and at the end of the study or day of death. Locomotor activity and food intake were assessed at baseline and day 10/11 after tumour inoculation for 24 h. RESULTS: Untreated tumour-bearing rats lost 55.3 ± 2.14 g body weight, which was reduced by low-dose to -39.6 ± 11.1 g (p = 0.0434) and high-dose IGF-1 to -42.7 ± 8.8 g (p = 0.057). Placebo-treated rats lost 41.4 ± 2.0-g lean mass, which was attenuated by low-dose IGF-1 (-28.8 ± 8.3 g, p = 0.041) and high-dose IGF-1 (-30.9 ± 7.4, p = 0.067). Spontaneous activity and food intake were improved by low-dose IGF-1 only. No effect on fat mass was observed. Low-dose IGF-1 significantly reduced mortality (HR = 0.45, 95%CI = 0.21-0.93, p = 0.0315), whilst the high dose did not reach significance (HR = 0.68, 95%CI = 0.26-1.74, p = 0.42). CONCLUSION: Low-dose IGF-1 reduced mortality and attenuated loss of body weight as well as muscle mass in the Yoshida hepatoma rat model. Moreover, an improved quality of life was observed in these animals. Further experiments using different doses are necessary.

No MeSH data available.


Related in: MedlinePlus

Weight of the M. gastrocnemius at the end of the study or the day of death. IGF-1-treated groups have a higher muscle weight. **p < 0.01
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3117996&req=5

Fig2: Weight of the M. gastrocnemius at the end of the study or the day of death. IGF-1-treated groups have a higher muscle weight. **p < 0.01

Mentions: As expected, a strong effect on tumour burden was seen on organ weight. The weight of the liver, spleen, kidney, brown adipose tissue (BAT), M. extensor digitalis longus (EDL), M. tibialis and M. gastrocnemius (Table 1 and Fig. 2) was improved by low-dose IGF-1. The high dose only improved the weight of BAT, EDL, M. tibialis and M. gastrocnemius (Table 1 and Fig. 2). Heart, lung, white adipose tissue (WAT, epididymal fat pad) and M. soleus did not show any changes in weight (Table 1).Table 1


IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.

Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J - J Cachexia Sarcopenia Muscle (2011)

Weight of the M. gastrocnemius at the end of the study or the day of death. IGF-1-treated groups have a higher muscle weight. **p < 0.01
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3117996&req=5

Fig2: Weight of the M. gastrocnemius at the end of the study or the day of death. IGF-1-treated groups have a higher muscle weight. **p < 0.01
Mentions: As expected, a strong effect on tumour burden was seen on organ weight. The weight of the liver, spleen, kidney, brown adipose tissue (BAT), M. extensor digitalis longus (EDL), M. tibialis and M. gastrocnemius (Table 1 and Fig. 2) was improved by low-dose IGF-1. The high dose only improved the weight of BAT, EDL, M. tibialis and M. gastrocnemius (Table 1 and Fig. 2). Heart, lung, white adipose tissue (WAT, epididymal fat pad) and M. soleus did not show any changes in weight (Table 1).Table 1

Bottom Line: No effect on fat mass was observed.Low-dose IGF-1 significantly reduced mortality (HR = 0.45, 95%CI = 0.21-0.93, p = 0.0315), whilst the high dose did not reach significance (HR = 0.68, 95%CI = 0.26-1.74, p = 0.42).CONCLUSION: Low-dose IGF-1 reduced mortality and attenuated loss of body weight as well as muscle mass in the Yoshida hepatoma rat model.

View Article: PubMed Central - PubMed

ABSTRACT
BACKGROUND: A hallmark symptom of cancer cachexia is the loss of skeletal muscle. This is at least partially due to a deregulation of the growth hormone/IGF-1 axis and a subsequently impaired protein synthesis in skeletal muscle. Here, we investigated the effect of IGF-1 supplementation in a rat model of cancer cachexia. METHODS: Juvenile rats were inoculated with the Yoshida AH-130 hepatoma and treated once daily with 0.3 mg kg(-1) day(-1) (low dose) or 3 mg kg(-1) day(-1) (high dose) IGF-1 or placebo for a period of maximal 16 days. Body weight and body composition (by NMR) were assessed at baseline and at the end of the study or day of death. Locomotor activity and food intake were assessed at baseline and day 10/11 after tumour inoculation for 24 h. RESULTS: Untreated tumour-bearing rats lost 55.3 ± 2.14 g body weight, which was reduced by low-dose to -39.6 ± 11.1 g (p = 0.0434) and high-dose IGF-1 to -42.7 ± 8.8 g (p = 0.057). Placebo-treated rats lost 41.4 ± 2.0-g lean mass, which was attenuated by low-dose IGF-1 (-28.8 ± 8.3 g, p = 0.041) and high-dose IGF-1 (-30.9 ± 7.4, p = 0.067). Spontaneous activity and food intake were improved by low-dose IGF-1 only. No effect on fat mass was observed. Low-dose IGF-1 significantly reduced mortality (HR = 0.45, 95%CI = 0.21-0.93, p = 0.0315), whilst the high dose did not reach significance (HR = 0.68, 95%CI = 0.26-1.74, p = 0.42). CONCLUSION: Low-dose IGF-1 reduced mortality and attenuated loss of body weight as well as muscle mass in the Yoshida hepatoma rat model. Moreover, an improved quality of life was observed in these animals. Further experiments using different doses are necessary.

No MeSH data available.


Related in: MedlinePlus